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Abstract
Candidaemia is associated with high patient mortality. Among those who survive an initial episode of candidaemia, the incidence of
recurrent episodes has been incompletely deﬁned. All patients in Iceland with candidaemia in 1980–2008 were identiﬁed, and clinical
information was reviewed. Episodes of candidaemia in the same patient were considered to be separate if they occurred ‡1 month
apart or were caused by different Candida species. The isolates were genotyped by using PCR ﬁngerprinting, and antifungal susceptibility
was determined. During the 29-year period, candidaemia was diagnosed in 307 patients in Iceland, 298 of whom (97.1%) had a single
episode. Overall, 206 patients survived >1 month from the ﬁrst episode and were therefore at risk of recurrence, yielding
1062 patient-years of observation in the survivors. Of those, nine (4.4%) later developed recurrent candidaemia. The median time
between recurrences was 6 months (range, <1 month to 14 years). Patients with late recurrences were younger (p 0.012) and more
likely to have underlying gastrointestinal diseases than patients with single episodes (55.6% vs. 18.5%, respectively; p 0.017). The recur-
rences were caused by identical Candida sp. genotypes in two of 13 cases (15%), but by different species or dissimilar genotypes in eight
of 13 (62%); isolates were missing in three cases. In conclusion, late recurrent candidaemia was a relatively rare event, and younger
patients with gastrointestinal disorders were more prone to recurrent infections. The majority of late recurrences represented
re-infections with new Candida strains that were susceptible to common antifungal agents.
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Introduction
The incidence of invasive fungal infections has increased dra-
matically worldwide over the past three decades [1–4]. Can-
dida species, in particular, are common causes of nosocomial
bloodstream infections (BSIs) in critically ill patients [5]. Risk
factors for candidaemia have been identiﬁed and extensively
described for adult and paediatric patients. They include
immunosuppression associated with neutropenia and/or cor-
ticosteroid therapy, renal failure, multiple or prolonged anti-
microbial therapy, indwelling central venous catheters, and
prior abdominal surgery [6–8]. Candidaemia has a major
impact on patient outcome, in terms of both morbidity and
mortality [9,10] and increased length of hospital stay [11,12].
Among those who survive the initial episode of candida-
emia, there have been increasing reports of recurrent Can-
dida BSIs, often occurring months after the initial episode
[13–17]. However, the incidence of late recurrent candida-
emia has not been previously evaluated in population-based
studies, and risk factors speciﬁc to recurrent BSIs remain
incompletely deﬁned. A study of risk factors for recurrent
candidaemia may help to identify subpopulations that could
beneﬁt from alternative treatment approaches.
Various typing methods have been used to study the phy-
logeny of Candida strains and detect nosocomial outbreaks
or clusters in the hospital environment. Currently, PCR-
based and sequence-based methods are the most widely
used. PCR ﬁngerprinting and random ampliﬁcation of
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polymorphic DNA have high discriminatory power for
related and unrelated isolates of clinically relevant Candida
species, and show strong concordance with other established
methods, including multilocus sequence typing [18–20]. Sev-
eral studies of repeated episodes of candidaemia have used
molecular typing methods in order to determine whether
subsequent episodes result from a re-infection with a new
strain or from relapse of an original infecting strain. They
suggest that the majority of these episodes represent persis-
tent rather than recurrent infections [13,15,17,21].
We used a nationwide registry of Candida BSIs in Ice-
land to identify all cases of late recurrent candidaemia dur-
ing a 29-year period, 1980–2008. The purpose of this
long-term study was to study the population-based inci-
dence, risk factors and clinical presentation of these rare
events, and to look for genetic relatedness among strains
recovered from initial and subsequent episodes by using
molecular typing.
Materials and Methods
Setting
Iceland is a 103 000-km2 island in the North Atlantic, with a
population of 226 948 at the beginning of the study period
and 319 368 at the end of 2008. During the study, two uni-
versity hospitals and 11–14 community hospitals were oper-
ating in the country. Three clinical microbiology laboratories
performed blood cultures on samples from all of the hospi-
tals, and one of them serves as the national reference labora-
tory for the country. This study was approved by the
National Bioethics Committee of Iceland and the Data Pro-
tection Authority of Iceland.
Collection of data
All patients in Iceland who had Candida spp. isolated from
blood during the period 1 January 1980 to 31 December
2008 were identiﬁed retrospectively by a nationwide search
in microbiology databases. Patient charts of all candidaemic
patients were reviewed and clinical data were collected,
including concomitant conditions, risk factors for candida-
emia, and treatment received. We calculated the case-fatality
rate among candidaemic patients within 7 and 30 days of
diagnosis, respectively, from hospital records and the
national population registry of Iceland.
Case deﬁnitions
An episode of candidaemia was deﬁned as one or more
blood cultures positive for Candida species. Late recurrent
candidaemia was deﬁned as a second episode of candidaemia
occurring at least 30 days after the last positive blood cul-
ture positive for Candida [13,22] or a second episode caused
by different Candida species. The source of candidaemia was
considered to be catheter-related if culture of the catheter
tip grew the same species isolated from blood.
Microbiology
All obtainable Candida bloodstream isolates were collected
from hospital laboratories throughout the country. The old-
est isolates in the collection date from 1990. In total, 262
isolates were viable and thus available for further study, rep-
resenting isolates from 242 (95.3%) of 254 episodes diag-
nosed in the country during 1991–2008. The isolates were
subcultured on Sabouraud agar (Oxoid, Basingstoke, UK).
Species identiﬁcation was based on germ-tube production,
culture on CHROMagar (Hardy Diagnostics, Santa Maria,
CA, USA), and the API id32C system (bioMe´rieux, Marcy
l’Etoile, France). MICs for amphotericin B, ﬂuconazole and
itraconazole were measured by using the Etest (AB Biodisk,
Solna, Sweden) according to CLSI criteria [23]. For episodes
where the isolates were not available, we relied on the spe-
cies identiﬁcation made at the time of diagnosis.
DNA ﬁngerprinting and genotyping
In total, 17 of the 22 Candida bloodstream isolates cultured
from patients with late recurrent episodes of candidaemia
were available for genotyping. Genomic DNA was extracted
as described previously [24]. Genotypes were determined by
amplifying genomic DNA with arbitrarily primed PCR, using
two separate primers (M13 and (GACA)4), as described in
detail elsewhere [18]. The ampliﬁcation products were sized
and scored manually and with BioNumerics, version 4.61
(Applied Maths, Sint-Martens-Latem, Belgium), with 0.5%
optimization and 1% position tolerance settings. A dendro-
gram was generated by using the Dice coefﬁcient and the un-
weighted pair group method with the use of average
linkages. Isolates with a percentage of similarity lower than
90% were considered to be unrelated.
Statistical analysis
We used Fisher’s exact test and Pearson’s chi-square test, as
appropriate, to assess the bivariate relationship between cat-
egorical variables, in particular whether patient groups with
single or recurrent episodes of candidaemia differed with
respect to underlying diseases, predisposing conditions, and
treatment. Age was compared between the groups by using
the Mann–Whitney test. All tests were two-sided, and the
level of signiﬁcance was set at p <0.05. Statistical analyses
were performed with SPSS version 11.0 (SPSS, Chicago, IL,
USA).
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Results
Epidemiology of candidaemia
From 1980 to 2008, 320 episodes of candidaemia, in 307
patients, were identiﬁed in Iceland, ranging from two to four
cases per year during 1980–1983 to 22 cases per year in
2007. In total, 298 patients (97.1%) had a single episode of
infection. The average population-based incidence of candida-
emia during this 29-year period was 3.98 cases per 100 000
population per year, increasing from 1.44 cases per 100 000
population per year during 1980–1984 to 6.12 during 2005–
2008 (p <0.001).
Late recurrent candidaemia
Overall, 206 patients survived for >30 days from the ﬁrst
candidaemic episode, and were therefore at risk of recur-
rence (1062 patient-years of observation). Of those, nine
(4.4%) later developed recurrent candidaemia; seven had two
episodes, one had three episodes, and one had ﬁve separate
episodes. In the at-risk group, the incidence of recurrent
candidaemia was 42.2 recurrences per 100 000 patients per
patient-year. Patient characteristics, treatment and outcome
of recurrent candidaemia are detailed in Table 1. The median
time between recurrences was 6 months, but varied greatly,
ranging from <1 month to 14 years. Recurrent episodes
(n = 13) were most commonly caused by Candida albicans
(46%), followed by Candida parapsilosis (15%) and Candida
tropicalis (15%) The proportion of BSIs caused by C. albicans
vs. non-albicans Candida spp. did not differ signiﬁcantly
between patients with single or initial episodes (61.5% (201
of 327) vs. 37.3% (122/327)) and patients with recurrent epi-
sodes (46.2% (6/13) vs. 53.8% (7/13); p 0.258).
Risk factors and treatment approaches for late recurrent
candidaemia
A comparison of major concomitant conditions, risk factors
and treatment approaches between patients with single and
recurrent episodes of candidemia is given in Table 2. Patients
with late recurrences were signiﬁcantly younger (median,
31 years; range, 1–68 years) than patients with a single infec-
tion (median, 64 years; range, 0–96 years; p 0.012). Addition-
ally, a signiﬁcantly higher proportion of patients with
recurrences had underlying gastrointestinal diseases (55.6%
(5/9) vs. 18.5% (53/286), respectively; p 0.017), including
inﬂammatory bowel disease, intestinal obstruction and/or
ischaemia, and liver diseases. A large proportion of patients
with late recurrent candidaemia had abdominal surgery
(44%), renal failure (33%), or diabetes (22%), but the differ-
ence did not reach statistical signiﬁcance. Patients with
recurrences did not differ from those with a single episode
with regard to therapeutic measures or source of infection
(data not shown).
PCR ﬁngerprinting of isolates from patients with recurrent
episodes
PCR ﬁngerprinting was performed on 17 viable strains, which
were responsible for 77.2% of recurrences. Genetic relation-
ships between the strains are shown in Fig. 1. The PCR
ﬁngerprinting and antifungal susceptibility testing results are
summarized in Table 3. The recurrences were caused by
identical Candida sp. genotypes in two of 13 cases (15%), but
by dissimilar genotypes or different species in eight of 13
cases (62%); isolates were missing in three cases. No
increase in antifungal resistance was documented in the
recurrent isolates (Table 3).
Discussion
To our knowledge, this is the ﬁrst long-term, population-
based study of late recurrent candidaemia. We used molecular
TABLE 2. Selected concomitant conditions, risk factors and
treatment approaches for 298 patients with a single candi-
daemic episode as compared with nine patients who later
developed late recurrent candidaemia
Variable
Single episode
(n = 298)a
Recurrent
episodes
(n = 9)b p
Age (years), median (range) 64 (0–96) 31 (1–68) 0.012
Male 168 (56.4) 4 (44.4) 0.513
Underlying conditions
Gastrointestinal disease 53 (18.5) 5 (55.6) 0.017
Diabetes 24 (8.4) 2 (22.2) 0.183
Renal failure 43 (15.0) 3 (33.3) 0.151
Solid organ malignancy 81 (28.3) 0 (0) 0.121
Haematological malignancy 29 (10.1) 1 (11.1) 1.0
Risk factor
Preceding infectionc 237 (83.7) 6 (66.7) 0.178
Bacteraemia 102 (36.0) 5 (55.6) 0.296
Line infection 26 (9.2) 1 (11.1) 0.588
Previous abdominal surgeryd 114 (40.0) 4 (44.4) 1.0
Previous antimicrobial therapyc 252 (89.4) 8 (100) 1.0
Corticosteroidsc 72 (26.8) 1 (14.3) 0.680
Neutropeniae 22 (7.8) 1 (11.1) 0.529
Vascular catheterf 244 (87.1) 7 (77.8) 0.635
CVC 237 (84.6) 7 (77.8) 0.635
Treatment approaches
CVC promptly removedg 154 (70.3) 4 (57.1) 0.432
Antifungal therapy 218 (76.8) 7 (77.8) 1.0
Combined prompt CVC
removal and antifungal therapy
127 (57.7) 4 (57.1) 1.0
CVC, central venous catheter.
Data are no. (%) of patients, unless indicated otherwise.
aClinical data available for 286 patients by chart review.
bClinical data regarding antimicrobial therapy missing for 1 patient and corticos-
teroid use for 2 patients.
cWithin 2 weeks before a positive blood culture sample was obtained.
dWithin 1 month of candidaemia.
eAbsolute neutrophil count of £500 cells/mm3.
fIncluding CVC, arterial line, dialysis catheter and Swan-Ganz catheter.
gWithin 48 h from diagnosis of candidaemia.
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methods to compare the genotypes of sequential isolates,
and the observation period was long (1062 patient-years).
According to our data, late recurrent candidaemia is a rela-
tively rare event, occurring in 4.4% of patients who survive
the initial episode, but the incidence is close to ten-fold
higher than in the general population.
The median time between the ﬁrst episode of candidaemia
and the recurrence (or between recurrences) was 6 months,
ranging from <1 month to 14 years. The interval between
episodes in our study is longer than that reported by other
investigators. For example, Clancy et al. studied ﬁve ran-
domly selected cases of late recurrent candidaemia, deﬁned
as an episode of candidaemia caused by the same Candida
species and occurring at least 1 month after the last blood
culture that was positive for Candida. The median time
between recurrences was 1 month, ranging from 1 to
TABLE 3. Origins, genotypes and antifungal susceptibility patterns of 17 Candida bloodstream isolates tested
Patient
Initial
(I)/recurrent
(R) episode(s) Isolate Candida spp.
Date of
isolation
(day/month/year)
MIC
ﬂuconazole
(lg/mL)
MIC
amphotericin B
(lg/mL)
MIC
itraconazole
(lg/mL)
Fingerprinting
genotypea
P1 I NA C. albicans 7/12/1990 NA NA NA –
R IS-70 C. tropicalis 23/3/1992 0.38 0.25 0.047 VIII
P2 I IS-13 C. parapsilosis 11/7/1994 1.0 0.19 0.047 VI
R IS-209 C. parapsilosis 5/9/1994 0.5 0.19 0.064 VI
P3 I IS-19 C. albicans 9/8/1995 0.38 0.094 0.032 II
R IS-20 C. albicans 9/9/1995 0.38 0.094 0.032 II
P4 I IS-63 C. albicans 6/12/1999 0.125 0.064 0.023 Ib
R IS-64 C. glabrata 16/12/1999 8.0 0.25 0.25 X
P5 I IS-122 C. albicans 5/2/2001 0.19 0.19 0.047 II
R IS-224 C. albicans 5/12/2006 0.25 0.003 0.032 Ia
P6 I IS-134 C. tropicalis 9/3/2002 0.75 0.19 0.032 VIII
R IS-0073 C. tropicalis 6/8/2007 0.38 0.25 0.032 IX
P7 I NA C. albicans 19/2/1992 NA NA NA –
R NA C. albicans 20/8/1992 NA NA NA –
P8 I IS-140 C. albicans 20/7/2002 0.094 0.094 0.047 Ia
R1 IS-144 C. parapsilosis 5/12/2002 0.25 0.25 0.023 VI
R2 IS-0239 C. albicans 8/12/2008 0.19 0.032 NA V
P9 I NA C. albicans 9/8/1981 NA NA NA –
R1 NA non-albicans
Candida
21/11/1983 NA NA NA –
R2 IS-38 C. dubliniensis 3/11/1997 0.125 0.047 0.008 VII
R3 IS-123 C. albicans 10/2/2001 0.047 0.016 0.004 III
R4 IS-136 C. albicans 7/4/2002 0.19 0.032 0.047 IV
NA, not available.
aBased on results of PCR ﬁngerprinting with the M13 primer.
FIG. 1. Dendrogram of the genetic relationships between 17 Candida bloodstream isolates from patients with recurrent candidaemia, based on
results from PCR ﬁngerprinting with the M13 primer. The dendrogram was constructed with the Dice coefﬁcient and the unweighted pair group
method with the average linkages cluster method. Genotypes are indicated on the right.
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8 months [13]. Other studies of recurrent candidaemia have
reported an interval from 1 to 6 months [14–17], whereas
persistent Candida prosthetic valve endocarditis has been
reported to occur up to 3 years following the initial infection
[25]. These previous case series and case reports lack the
population-based design and long-term follow-up provided by
this study.
Outbreaks or clusters of identical genotypes of Candida
causing BSIs have previously been shown to have the ability
to smoulder over a long period of time, even years [18].
The most common reason for recurrences in the current
study was the persistence of particular risk factors for candi-
daemia among the patients, rather than relapses from inade-
quately treated infections. Many of the patients had chronic
underlying diseases, such as diabetes, gastrointestinal dis-
eases, or malignancy, requiring frequent antimicrobial and/or
immunosuppressive therapy. Patients with recurrences did
not differ from those with a single episode with regard to
most risk factors or therapeutic measures (removal of cen-
tral venous catheters and antifungal therapy). This contrasts
with studies reporting a high proportion of retained intravas-
cular catheters among patients who developed persistent or
recurrent candidaemia [13,21]. In our cohort, a signiﬁcantly
higher proportion of patients with recurrences had underly-
ing gastrointestinal diseases, and a large proportion had pre-
vious abdominal surgery. Similarly, in the study by Clancy
et al. [13], two of the ﬁve patients with recurrent candida-
emia had previous abdominal surgery and underlying gastro-
intestinal diseases. The gastrointestinal tract is an important
site of Candida colonization. Invasion of infecting isolates
could occur because of disruption of the barrier function of
the gastrointestinal mucosa in relation to the comorbid gas-
trointestinal diseases, i.e. as a result of mucositis, perfora-
tion, or surgery [26]. In our patient cohort, none of the
patients had evidence of another nidus of infection at the
time of diagnosis of the recurrent infection. Therefore, the
gastrointestinal tract may be the most important source of
infecting isolates in this population.
By genotyping the isolates with PCR ﬁngerprinting, we
found that at least 62% of late recurrences represented re-
infections with new Candida species or new strains. Only
two (15%) of 13 recurrences were caused by identical geno-
types, suggesting relapse; in both cases, there was a relatively
short interval between the initial and recurrent episodes of
candidaemia (1 and 2 months, respectively). Similarly, a study
by Shin et al. [17] of persistent and recurrent Candida BSIs
showed that two of three cases of recurrences, which
occurred at least 1 month apart (range, 1–5 months), were
caused by strains of different karyotypes as determined by
pulsed-ﬁeld gel electrophoresis. However, this is in contrast
to most previous studies, where identical Candida strains
have been found to be responsible for most episodes of
recurrent candidaemia. Clancy et al. [13] used restriction
enzyme analysis and inter-repeat PCR for typing of isolates
from ﬁve cases of late recurrent candidaemia, and showed
that the recurrent episodes were all caused by the same Can-
dida strain as the initial episode. Another study reported
three episodes of C. parapsilosis fungaemia in a cancer patient
caused by strains with identical pulsed-ﬁeld gel electrophore-
sis karyotypes [16], and a recent study that included two
patients with recurrent candidaemia showed identical
sequence types in the initial and subsequent isolates [15].
There are at least two possible explanations for these differ-
ent ﬁndings. First, because of the long observation period in
our study, we were able to identify recurrences occurring
years after the initial episode, which are therefore more
likely to represent endogenous or exogenous re-infections
rather than persistence or relapse of an infecting isolate. Sec-
ond, different genotypes of Candida isolates of the same spe-
cies, cultured from the same individual several months or
years apart, might reﬂect micro-evolutionary changes over a
long period of time, which may have been the case in
patients 5 and 6. Previous studies have shown that loss of
heterozygosity may explain differences in genotype observed
among C. albicans isolates during sequential cultures from the
same patient [27,28]. Furthermore, recent data suggest that
genetic variants of the same strain, recovered from a patient
during recurrent Candida infections, can become progres-
sively less virulent in animal models [29]. For recurrences,
we did not document a signiﬁcant change in antifungal sus-
ceptibility patterns, and all isolates tested were susceptible
to ﬂuconazole and amphotericin B. This is in concordance
with previous reports of late recurrent candidaemia [13,17].
In summary, this nationwide study investigated the inci-
dence, risk factors and molecular epidemiology of late recur-
rent candidaemia over a long observation period. This was a
relatively rare event, occurring in 4.4% of patients who sur-
vived the initial candidaemic episode. Furthermore, in con-
trast to most previous studies, genotyping of the isolates
showed that a majority of recurrences were caused by new
Candida species or new strains. Our data also point towards
the gastrointestinal tract as a continuous source of infection
among patients with non-life-threatening gastrointestinal ill-
nesses. Further studies may help to identify patient groups
that could beneﬁt from more intensive follow-up or pro-
longed antifungal therapy.
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